Leronlimab is supposed to block the CCR5 cell receptor from causing inflammation in the lungs. Under an emergency approval by the FDA, the drug was used on a handful of patients with severe cases of COVID-19 in New York. CEO and President of CytoDyn Rader Pourhassan says several of the patients came off of ventilators.